Alexis Régent1, Serge Redeker1, Alban Deroux1, Pierre Kieffer1, Kim Heang Ly1, Maxime Dougados1, Eric Liozon1, Claire Larroche1, Loïc Guillevin1, Laurence Bouillet1, Olivier Espitia1, Nathalie Costedoat-Chalumeau1, Martin Soubrier1, Benoît Brihaye1, François Lifermann1, Guillaume Lefevre1, Xavier Puéchal1, Luc Mouthon1, Eric Toussirot1. 1. From the Université Paris-Descartes; APHP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, service de médecine interne, Paris; Service de médecine interne, Centre hospitalier d'Abbeville, Abbeville; Service de médecine interne, Université Grenoble Alpes, Centre Hospitalier Universitaire (CHU) de Grenoble, Grenoble; Service de médecine interne, Centre Hospitalier Général de Mulhouse, Mulhouse; Service de médecine interne, CHU de Limoges, Limoges; Department of Rheumatology, Hôpital Cochin, APHP; INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris; Service de médecine interne, Hôpital Avicenne, Bobigny; Service de médecine interne, Hôpital Hôtel-Dieu, Nantes; Service de rhumatologie, CHU de Clermont-Ferrand, Clermont Ferrand; Service de médecine interne et médecine polyvalente, Hôpital de Saint Quentin, Saint Quentin; Service de médecine interne, CH de Dax, Dax; Service de médecine interne, Hôpital Claude Huriez, Lille; Centre d'Investigation Clinique Biothérapie INSERM CIC-1431, FHU INCREASE, Service de rhumatologie, Centre Hospitalier Régional Universitaire (CHRU), Besançon, France.A. Régent, MD, PhD, Université Paris-Descartes; APHP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, service de médecine interne; S. Redeker, MD, Service de médecine interne, Centre hospitalier d'Abbeville; A. Deroux, MD, Service de médecine interne, Université Grenoble Alpes, CHU de Grenoble; P. Kieffer, MD, Service de médecine interne, Centre Hospitalier Général de Mulhouse; K.H. Ly, MD, PhD, Service de médecine interne, CHU de Limoges; M. Dougados, MD, PhD, Université Paris-Descartes, Department of Rheumatology, APHP, Hôpital Cochin, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité; E. Liozon, MD, Service de médecine interne, CHU de Limoges; C. Larroche, MD, Service de médecine interne, Hôpital Avicenne;
Abstract
OBJECTIVE: To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA). METHODS: A retrospective multicenter study that included 34 patients receiving TCZ for GCA. RESULTS: TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months. CONCLUSION: TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.
OBJECTIVE: To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA). METHODS: A retrospective multicenter study that included 34 patients receiving TCZ for GCA. RESULTS:TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months. CONCLUSION:TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.
Authors: Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta Journal: Nat Rev Rheumatol Date: 2017-09-14 Impact factor: 20.543
Authors: Maria Gabriella Raimondo; Martina Biggioggero; Chiara Crotti; Andrea Becciolini; Ennio Giulio Favalli Journal: Drug Des Devel Ther Date: 2017-05-24 Impact factor: 4.162